Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma.

Bone marrow aspirates from 306 patients with multiple myeloma were analyzed by flow cytometric immunophenotyping. The plasma cells (PCs) were identified by their characteristic light scatter distribution and reactivity patterns to CD138, CD38, and CD45. Monoclonality was confirmed by immunoglobulin light chain analysis. The immunophenotypic profile of the PCs was determined with a panel of antibodies. Moderate to bright expression of CD56, CD117, CD20, CD45, and CD52 was detected in 71.7%, 17.8%, 9.3%, 8.8%, and 5.2% of cases, respectively. These antigens were expressed by a distinct subpopulation of the PCs in 6.3%, 2.2%, 3.7%, 2.9%, and 2.6% of additional cases. CD19 was negative in more than 99% of cases. The combination of CD38 and CD138 was superior to CD38 alone for identifying CD45+ myeloma and separating CD20+ myeloma from B-cell lymphoma. PC immunophenotyping might be useful for detecting minimal residual disease in cases with aberrant antigen expression and for selection of therapeutic agents that have specific membrane targets.

[1]  R. Ohno,et al.  Clinicopathological and prognostic characteristics of CD56‐negative multiple myeloma , 2002, British journal of haematology.

[2]  S. Treon,et al.  The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. , 2000, Seminars in oncology.

[3]  M. Dhodapkar,et al.  Syndecan-1 (CD138) Immunoreactivity in Bone Marrow Biopsies of Multiple Myeloma: Shed Syndecan-1 Accumulates in Fibrotic Regions , 2001, Modern Pathology.

[4]  Shaji K. Kumar,et al.  Expression of CD52 on plasma cells in plasma cell proliferative disorders. , 2003, Blood.

[5]  B. Barlogie.  Plasma cell myeloma , 2001 .

[6]  A. Órfão,et al.  Expression of the CD117 antigen (C‐Kit) on normal and myelomatous plasma cells , 1996, British journal of haematology.

[7]  S. Ely,et al.  Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation. , 2002, The American journal of pathology.

[8]  Ana Helena Santos,et al.  Immunophenotypic aberrations, DNA content, and cell cycle analysis of plasma cells in patients with myeloma and monoclonal gammopathies. , 2000, Blood cells, molecules & diseases.

[9]  原田 浩徳.  Phenotypic difference of normal plasma cells from mature myeloma cells , 1993 .

[10]  B. Barlogie,et al.  Cytoplasmic immunoglobulin content in multiple myeloma. , 1985, The Journal of clinical investigation.

[11]  C. D. Wu,et al.  Differential diagnosis of malignant lymphomas and related disorders by specific pattern of expression of immunophenotypic markers revealed by multiparameter flow cytometry (Review). , 2000, International journal of oncology.

[12]  B. Klein,et al.  A plasmocyte selective monoclonal antibody (B‐B4) recognizes syndecan‐1 , 1996, British journal of haematology.

[13]  T. Therneau,et al.  Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia. , 1998, Leukemia & lymphoma.

[14]  S. Barrans,et al.  Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression , 1999, British journal of haematology.

[15]  A. Órfão,et al.  High‐sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma , 1999, British journal of haematology.

[16]  T. Rasmussen,et al.  Differential expression of CD56 and CD44 in the evolution 
of extramedullary myeloma , 2002, British journal of haematology.

[17]  M. Jourdan,et al.  The myeloma cell antigen syndecan‐1 is lost by apoptotic myeloma cells , 1998, British journal of haematology.

[18]  A. Órfão,et al.  Optimal number of reagents required to evaluate hematolymphoid neoplasias: results of an international consensus meeting. , 2001, Cytometry.

[19]  G. Morgan,et al.  Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage , 1997, British journal of haematology.